Hair Relaxer Lawsuit Update: Judge Admits Four More Cancer Experts, Excludes Two in MDL 3060
In the latest hair relaxer lawsuit update, Judge Mary Rowland ruled on November 12 on six more plaintiffs' general causation experts, admitting four and excluding two. Eight of the ten challenged experts are now decided, and the 12,743-case MDL keeps its 2027 trial path.
Torts Desk··23 min read

The newest hair relaxer lawsuit update is a second expert ruling: on Thursday, November 12, 2026, U.S. District Judge Mary M. Rowland of the Northern District of Illinois denied the defendants' motion to exclude four more of the plaintiffs' general causation experts and granted it as to two. Combined with her October 22 ruling admitting the plaintiffs' lead epidemiologist, the order means eight of the ten challenged experts have now been decided, most of them in the plaintiffs' favor, and the 12,743-case federal litigation, In re Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation, MDL No. 3060, stays on track for bellwether trials in 2027.
The ruling is a split, and both halves matter. The defendants, led by L'Oréal USA, Revlon and Strength of Nature, won the exclusion of two witnesses, which narrows the scientific case the plaintiffs can present to a jury. But the core of the plaintiffs' General Causation case, the epidemiology tying chemical straighteners to uterine and ovarian cancer, survived in October, and four more experts have now cleared the gate under amended Federal Rule of Evidence 702. The defense route to a docket-wide dismissal, the outcome that ended the federal baby food autism claims and, for three years, the acetaminophen litigation, is close to shut.
What is the latest hair relaxer lawsuit update?
The latest hair relaxer lawsuit update is the November 12, 2026 order on the defendants' May 5, 2026 joint motion to exclude the plaintiffs' general causation experts. Mealey's reported on November 13 that the court granted exclusion of two experts and denied exclusion of four others. A plaintiff-side summary of the MDL docket describes the same result in the same numbers (six more experts decided, four allowed, two excluded) and identifies the order as Dkt. 2092 on the master docket, No. 1:23-cv-00818.
That is the second installment of a ruling the court has been issuing in pieces:
- October 22, 2026 (Dkt. 2079). Judge Rowland denied the motion as to the plaintiffs' epidemiologist, Dr. Cote, and granted it in part as to toxicologist Mr. Atwood. Reporting on that order says the court cut Mr. Atwood's opinions on inhalation exposure but let him testify that endocrine-disrupting chemicals in relaxers make a cancer link biologically plausible, including through absorption into the skin.
- November 12, 2026 (Dkt. 2092). Six more experts decided: four admitted, two excluded.
- Still pending. On the ten-expert count reported for the May motion, two experts remain undecided, and the court has said a further order will follow. No date has been set for it.
Everything else on the docket is unchanged. No hair relaxer case has been tried, no global settlement has been announced, and the court has not ruled on class certification. The first federal bellwether trial remains set for September 2027.
What did the judge decide about the hair relaxer experts on November 12?
Judge Rowland decided that four of the six general causation experts addressed in the November 12 order may testify and that two may not. In Rule 702 terms, she found that the plaintiffs had shown by a preponderance of the evidence that the four admitted experts' opinions rest on sufficient facts and reliable methods, reliably applied, and that the plaintiffs had not made that showing for the other two.
The reasoning of the November order has not been published in any source available at the time of writing, and the order itself had not been posted to a free public repository. What is known about the court's approach comes from the October 22 opinion, which reports variously describe as 65 or 78 pages long, and which set the framework the November order applies. On the reported descriptions of that opinion:
- Generalized objections are not categorical bars. The defendants raised several objections that applied across all ten experts. The court held that those objections did not, on their own, require exclusion; each expert's opinion had to be tested on its own methodology.
- A mixture can be the exposure. The plaintiffs may treat chemical relaxers as finished products, a mixture of constituents, without identifying the single chemical or the precise product recipe responsible. According to plaintiffs' co-lead firm DiCello Levitt, experts may evaluate relaxers as finished products provided their methods are reliable.
- Every step still has to hold. Each expert must still reliably bridge every step of the analysis from data to conclusion. That is the language of amended Rule 702(d), and it is the standard under which the two experts excluded on November 12 presumably failed.
The October framework explains the November split. A court that accepts a mixture as the exposure and refuses to apply blanket objections will admit most experts whose methods are conventional. It will still exclude an expert whose particular chain of reasoning has a gap: an opinion extrapolated beyond the data, a dose assumption without support, or a route of exposure (as with Mr. Atwood's inhalation opinions) that the record does not establish.
Which hair relaxer experts were excluded?
The identities of the two hair relaxer experts excluded on November 12 have not been reported. Mealey's, the plaintiff-side docket summary, and every hair relaxer lawsuit update page reviewed for this article give the four-to-two count without naming the witnesses, and the order is not yet available outside PACER. This article does not guess.
What the record does establish is the universe the two came from. The May 2026 joint status report filed in the MDL lists the general causation experts the defendants moved to exclude on May 5, 2026: Atwood, Brown, Chang, Cote, Crowley, Panigrahy, Puglisese (as spelled in the report), Roque, Sharma and Zoeller. Two of those (Cote and Atwood) were decided in October. The two excluded on November 12 are among the remaining eight, and so are the two still pending.
The scorecard as of November 14, 2026:
| Ruling | Experts | Outcome | Source |
|---|---|---|---|
| Oct. 22, 2026 (Dkt. 2079) | Dr. Cote (epidemiology) | Motion to exclude denied | Mealey's; DiCello Levitt; docket summary |
| Oct. 22, 2026 (Dkt. 2079) | Mr. Atwood (toxicology) | Granted in part; inhalation-exposure opinions cut | Consumer Notice; docket summary |
| Nov. 12, 2026 (Dkt. 2092) | Four experts (not yet publicly named) | Motion to exclude denied | Mealey's; docket summary |
| Nov. 12, 2026 (Dkt. 2092) | Two experts (not yet publicly named) | Motion to exclude granted | Mealey's; docket summary |
| Pending | Two experts | Undecided; further order promised | Arithmetic from the ten-expert motion; docket summary |
| Total | 10 challenged | 6 admitted in full, 1 in part, 2 excluded, 2 pending |
Practitioners need the names, and they will matter. An excluded epidemiologist or biostatistician would weaken the plaintiffs more than an excluded expert on a narrow mechanism or on a single cancer type, because epidemiology carries general causation and mechanism testimony only supports it. The fact that the plaintiffs' central epidemiologist was admitted in October limits how damaging any single exclusion can be, but a firm advising clients should read Dkt. 2092 before telling them what it means for a particular cancer type.
How many hair relaxer experts can testify at trial?
As of November 14, 2026, six of the plaintiffs' ten challenged general causation experts may testify at trial: five in full and one, Mr. Atwood, in part. Two have been excluded and two are undecided.
The arithmetic runs as follows:
- Admitted in full: Dr. Cote (October 22) plus four experts (November 12) = 5.
- Admitted in part: Mr. Atwood (October 22) = 1.
- Excluded: two experts (November 12) = 2.
- Pending: 2.
So six of the ten will be on the plaintiffs' general causation witness list in some form, two will not, and two await a ruling. If both pending experts are admitted, the final tally will be eight of ten; if both are excluded, six of ten. On either outcome, the plaintiffs will have more general causation testimony available than they need to get a bellwether case to a jury, because one reliable epidemiologist plus supporting mechanism evidence is the conventional minimum.
The number of experts is not the same as the number of opinions. A ruling can admit an expert while trimming particular opinions, as the October order did with Mr. Atwood. Whether the four experts admitted on November 12 were admitted in full or with limitations has not been reported, and the bare four-to-two count may conceal partial rulings of the same kind.
Why the four-to-two split matters under amended Rule 702
Federal Rule of Evidence 702 was amended on December 1, 2023, to make explicit two points that some courts had treated loosely. First, the proponent of expert testimony must show that it is more likely than not that the admissibility requirements are met. Second, the expert's opinion must reflect a reliable application of the principles and methods to the facts of the case. The Advisory Committee's note criticized courts that had treated the sufficiency of an expert's basis and the application of the methodology as questions of weight for the jury rather than admissibility for the judge.
Defense counsel in every product liability MDL since then has used the amendment to press for full-docket exclusion of general causation experts. The theory is simple: if no admissible expert can testify that the product is capable of causing the disease, every case fails on General Causation, and the MDL court can enter summary judgment across the docket in a single order. That is what happened in the baby food MDL in 2026, and what happened in the acetaminophen MDL in December 2023 before the Second Circuit partly reversed.
Against that background, the hair relaxer rulings stand out for three reasons:
- The judge applied the amended standard and still admitted most experts. Judge Rowland excluded two experts and limited a third, which shows that the gatekeeping under Rule 702 was real rather than nominal. The admissions of the other six are harder to attack on appeal for that reason; an opinion that excludes no one invites the argument that the court treated reliability as a jury question.
- The plaintiffs' case does not depend on one witness. In the acetaminophen litigation, the plaintiffs' experts relied heavily on overlapping methodology, and the district court's critique of that methodology took down all of them at once. In the hair relaxer MDL, the experts were tested individually, and the court's acceptance of the finished-product approach removed the objection most likely to sink them together.
- Exclusions narrow the trial, not the docket. The two excluded experts' opinions will be unavailable at trial, which may limit how plaintiffs present particular cancer types, chemical constituents or exposure routes. But with the central epidemiology in, those exclusions shape the bellwether presentations rather than end the cases.
How the hair relaxer ruling compares with other MDL causation fights
The general causation gate has produced sharply different results in the large consumer product and pharmaceutical MDLs since the 2023 amendment. The table sets out where the hair relaxer litigation now sits.
| MDL | Court | General causation outcome | Effect on docket |
|---|---|---|---|
| Hair relaxer, MDL 3060 | N.D. Ill. (Rowland, J.) | Epidemiologist admitted, toxicologist limited (Oct. 22, 2026); four admitted, two excluded (Nov. 12, 2026); two pending | Bellwether track continues; first trial September 2027 |
| Baby food, MDL 3101 | N.D. Cal. (Corley, J.) | All but one general causation expert excluded (Feb. 27, 2026); surviving expert limited to biological plausibility | Partial summary judgment on autism and ADHD claims (Oct. 14, 2026) |
| Acetaminophen, MDL 3043 | S.D.N.Y. (Cote, J.); 2d Cir. | All plaintiffs' experts excluded (Dec. 2023); three reinstated on appeal (July 13, 2026) | About 500 cases revived; rehearing denied Oct. 16, 2026 |
| Depo-Provera, MDL 3140 | N.D. Fla. (Rodgers, J.) | Rule 702 and preemption motions briefed and argued in 2026 | Pfizer settlement program; registration closes Nov. 30, 2026 |
The comparison shows why the November 12 ruling matters even though the October ruling did the heavy lifting. In the baby food MDL, Judge Corley excluded all but one expert and limited that one to biological plausibility, and a plausibility opinion alone could not carry general causation. The result was summary judgment on the autism and ADHD claims eight months later. In the hair relaxer MDL, the plaintiffs keep an epidemiologist and at least five other experts. A defense summary judgment motion on general causation is no longer a realistic path.
One more point of comparison is unusual: Dr. Cote, the hair relaxer epidemiologist, shares a surname with Judge Denise Cote, who presided over the acetaminophen MDL and excluded the plaintiffs' experts in that case. They are different people, and the outcomes for the plaintiffs could hardly be more different.
Is the hair relaxer lawsuit still moving forward?
Yes. The hair relaxer lawsuit is still moving forward, and after the November 12 ruling the risk that it ends on general causation is remote. The two excluded experts narrow the plaintiffs' scientific case but do not remove its foundation, and the court has now admitted six of the ten challenged experts in whole or in part.
Several pieces of the litigation are proceeding at once:
- Federal bellwethers. Five bellwether cases are in expert discovery. HarrisMartin's reporting of the October 22 docket note identifies four: Bridget Boatwright, Carrie Chattman, Charlene Fennell and Gloria Ford, whose case is the only ovarian cancer claim in the group and is slotted to be tried third, fourth or fifth. The fifth plaintiff has not been confirmed in public reporting.
- Docket policing. The court is pruning noncompliant cases. After an October 7, 2026 hearing on missing Plaintiff Fact Sheet (PFS) and authorization obligations and on cases filed for deceased plaintiffs, Judge Rowland ordered dismissals, some with prejudice.
- Second Wave defendants. A later-added group of manufacturers is on a separate discovery track under Case Management Order No. 24, which runs to July 15, 2027.
- State attorney general suits. Arizona sued L'Oréal in September 2026 and Minnesota sued L'Oréal and SoftSheen-Carson on October 23, 2026, under state consumer protection statutes. Those actions do not require proof of causation, and they run independently of the MDL's expert rulings.
- State courts. Consolidated hair relaxer proceedings are pending in the Circuit Court of Cook County, Illinois, and claims in Georgia proceed under the Supreme Court of Georgia's 2025 Burroughs v. Strength of Nature Global, LLC decision, which held that the ten-year Statute of Repose runs from each retail sale. A federal Rule 702 ruling does not bind state courts, which apply their own expert standards.
What happens next in the hair relaxer MDL?
The next steps in the hair relaxer MDL are the ruling on the last two general causation experts, the close of case-specific expert discovery in the bellwether cases, and a round of summary judgment and case-specific Rule 702 motions in early 2027. The most recently reported schedule, from a plaintiff-side docket summary and a second tracker, runs as follows:
| Step | Reported date | Status |
|---|---|---|
| Rule 702 ruling on Dr. Cote and Mr. Atwood | Oct. 22, 2026 | Decided |
| Rule 702 ruling on six more experts | Nov. 12, 2026 | Decided (4 admitted, 2 excluded) |
| Ruling on remaining two general causation experts | Not scheduled | Pending |
| Close of expert discovery in the five bellwether cases | Dec. 21, 2026 | Upcoming |
| Summary judgment and case-specific Rule 702 motions | Jan. 11, 2027 | Upcoming |
| Oppositions | Feb. 10, 2027 | Upcoming |
| Replies | Feb. 24, 2027 | Upcoming |
| Monthly case management conferences | Jan.–Aug. 2027 | Scheduled |
| Close of Second Wave discovery (CMO No. 24) | July 15, 2027 | Scheduled |
| First bellwether trial | Sept. 7 (or 9), 2027 | Scheduled |
Some older trackers still list November 16 and December 16, 2026 as motion deadlines. Those dates appear to predate an amendment of the schedule; the December 21 and January 11 dates are the ones reported after the October ruling. The docket controls, and counsel should confirm against the operative case management order.
The January motions will be different in kind from the May motion. The May motion asked whether relaxers can cause cancer at all. The January motions will ask whether each bellwether plaintiff's case-specific experts can reliably attribute her cancer to relaxer use rather than to other risk factors, which is the Specific Causation question. That is where the two November 12 exclusions may matter most: if the excluded experts' opinions were ones the case-specific experts relied on, the defendants will argue that the case-specific opinions have lost part of their foundation.
When is the first hair relaxer trial?
The first federal hair relaxer bellwether trial is set for September 2027 in Chicago. A September 24, 2026 docket entry, as reported by trackers, set the start for Tuesday, September 7, 2027, while a HarrisMartin report gives September 9, 2027 and describes the first trial as one against L'Oréal USA. Both place it in the same week; the docket entry controls.
The November 12 ruling makes that date firmer. The principal risk to the trial schedule was a general causation ruling that removed the plaintiffs' ability to prove their case. With eight of ten experts decided and the epidemiologist in, that risk is now limited to the January summary judgment motions in individual bellwether cases. Those motions could remove one or more bellwether cases from the trial list, but the court has five cases in the pool precisely so that the first trial date survives if one or two drop out.
How many hair relaxer lawsuits are pending?
The Judicial Panel on Multidistrict Litigation's November 2, 2026 report lists 12,743 pending actions in MDL No. 3060 out of 17,018 filed since centralization on February 6, 2023. That is up 362 from 12,381 pending on October 1, 2026, and makes the hair relaxer docket the fourth-largest MDL in the federal courts by pending actions, behind talc, hernia mesh and AFFF.
The November figure carries a reconciliation caveat. The October report showed 16,828 actions filed, so the cumulative filed count rose by 190 in the month while the pending count rose by 362. Pending actions cannot ordinarily rise by more than new filings, which points to reinstated cases, a correction, or a reporting error. On a like-for-like basis the docket sits somewhere between 12,571 and 12,743 pending actions, and it is growing on either reading.
Filing behavior after the November 12 ruling will be telling. Firms that held unfiled hair relaxer claims until the general causation question was answered have had their answer for three weeks, and the second ruling confirms it. The December 2026 JPML report, which will capture filings through the end of November, is the first that will reflect both rulings.
Has there been a hair relaxer settlement?
No. As of November 14, 2026, there is no hair relaxer settlement, global or individual, announced in the federal MDL, and no hair relaxer plaintiff has been paid through it. The November 12 ruling does not create a settlement, and neither side has said publicly that negotiations are under way.
What the ruling does change is the pricing of any future Global Settlement. Before October 22, every claim in the docket carried the risk that the court would exclude the plaintiffs' causation evidence and enter judgment for the defendants across the board. A rational defendant discounts its settlement offers by that risk, and a rational plaintiffs' firm accepts some discount for it. After two rulings that leave the plaintiffs' causation case standing, that discount has largely disappeared. The remaining uncertainties are case-specific (cancer type, duration and frequency of use, Product Identification, competing risk factors) and they are the variables a Settlement Matrix is built to handle.
The Depo-Provera litigation is the comparison point the market is watching. There, Pfizer reached a settlement covering most of the MDL before Judge Rodgers ruled on general causation, at a point when the uncertainty still cut against the plaintiffs. The hair relaxer defendants did not settle before their ruling, and the ruling went largely against them. The next natural pressure point is the January 2027 summary judgment round, followed by the run-up to the first trial.
Any settlement program would also have to deal with the docket's composition. Uterine and endometrial cancer claims dominate the inventory, and four of the five bellwethers are uterine cancer cases; ovarian cancer claims are fewer and, on the epidemiology, less established. A ruling that excluded an expert whose opinions concerned a particular cancer type would bear directly on how a matrix values that type, which is another reason the identities of the two excluded experts matter.
What the science says, and what the exclusions cannot reach
The plaintiffs' general causation case rests on observational epidemiology, chiefly an analysis of the National Institute of Environmental Health Sciences' Sister Study published in October 2022. That study followed 33,497 women aged 35 to 74 for almost 11 years, during which 378 uterine cancers were diagnosed. Women who had used straightening products more than four times in the prior year had more than double the uterine cancer risk of never-users. The National Institutes of Health estimated cumulative uterine cancer risk by age 70 at 1.64% for never-users and 4.05% for frequent users.
Reporting on the October ruling says Dr. Cote's analysis of the literature found increased cancer risks among frequent users ranging from about 20% to about 250%. That range, which the court admitted, is the evidence a bellwether jury will hear on whether relaxers can cause cancer, and nothing in the November 12 ruling disturbs it. The two November exclusions removed other opinions, from witnesses whose specialties have not been disclosed; they did not touch the epidemiology the October order admitted.
The defense critiques remain available at trial as matters of weight: that the Sister Study is one cohort, that use was self-reported without brand detail, that the absolute number of cancers is small, and that confounding by other risk factors cannot be excluded. Admission under Rule 702 means a judge found the methodology reliable enough for a jury to hear; it is not a finding that the experts are right. As the October opinion is reported to have put it, the court's task was to assess the experts' methods rather than to decide the science.
Can the hair relaxer defendants appeal the expert rulings?
Not immediately. Rule 702 rulings are interlocutory orders, and a party ordinarily cannot appeal them until there is a final judgment. For the defendants, that means waiting for a verdict in a bellwether case and appealing the admission of the experts as part of an appeal from the judgment. The Seventh Circuit, which would hear that appeal, reviews a district court's Rule 702 rulings for abuse of discretion, a deferential standard.
The defendants could ask Judge Rowland to certify a controlling question of law for interlocutory appeal under 28 U.S.C. § 1292(b), but that route fits poorly. Rule 702 rulings are usually treated as applications of settled law to a particular record rather than pure questions of law, and the October opinion's central holding (that a finished-product mixture can be the exposure for general causation) is the kind of fact-bound reliability determination appellate courts rarely take up early.
For the plaintiffs, the two exclusions are equally unreviewable for now. Because the plaintiffs' cases continue on the admitted experts, there is no judgment from which to appeal, and the excluded opinions will simply be absent at trial. If a bellwether plaintiff loses, the exclusions can be raised on appeal from that judgment. The practical consequence is that the expert lineup set by the October and November orders, plus the forthcoming ruling on the last two experts, is the lineup for the first trials.
Hair relaxer lawsuit update: the MDL 3060 timeline
The November 12 order is the latest entry in a record that now runs more than four years from the publication of the study that started the litigation. The dates below are drawn from docket entries reported by litigation trackers, the JPML's statistics and this site's earlier coverage of the MDL.
| Date | Event |
|---|---|
| Oct. 17, 2022 | Sister Study analysis on straighteners and uterine cancer published |
| Feb. 6, 2023 | JPML centralizes federal cases as MDL No. 3060 before Judge Rowland in Chicago |
| Nov. 2023 | Court rejects the defendants' preemption argument and largely denies dismissal |
| Sept. 30, 2024 | Court mostly denies motions to dismiss and to strike class allegations |
| Jan. 8, 2026 | Science Day held before Judge Rowland |
| May 5, 2026 | Defendants move to exclude ten general causation experts under Rule 702 |
| June 16, 2026 | Rule 702 briefing closes |
| Sept. 2026 | First bellwether trial set for September 2027; Arizona sues L'Oréal |
| Oct. 7, 2026 | Hearing on PFS deficiencies and cases filed for deceased plaintiffs; dismissals follow |
| Oct. 22, 2026 | Dr. Cote admitted; Mr. Atwood limited in part; final five bellwethers named |
| Oct. 23, 2026 | Minnesota sues L'Oréal and SoftSheen-Carson |
| Nov. 2, 2026 | JPML report lists 12,743 pending actions |
| Nov. 12, 2026 | Four more experts admitted, two excluded (Dkt. 2092) |
| Dec. 21, 2026 | Reported close of bellwether expert discovery |
| Jan. 11, 2027 | Reported deadline for summary judgment and case-specific Rule 702 motions |
| Sept. 2027 | First bellwether trial |
Two patterns run through that record. The first is consistency: at each gateway (preemption in 2023, dismissal and class allegations in 2024, and general causation in 2026) the court has declined to end the litigation on a threshold ruling, while still granting the defendants narrower relief, such as the exclusion of two experts and the dismissal of deficient cases. The second is pace. Five months passed between the May motion and the first expert ruling, and three weeks between the first and the second; the court has kept the bellwether workup moving throughout rather than staying it to await the expert rulings. A defendant hoping that the remaining expert ruling or the January motions will slow the September 2027 trial has little in the record to rely on.
For anyone following the docket, the practical point of this hair relaxer lawsuit update is that the litigation has moved from the question of whether hair relaxers can cause cancer to the question of which plaintiffs can prove that they did.
What it means for claimants' counsel, defendants and funders
The November 12 ruling has different consequences for each group with a stake in the docket. None of what follows is legal advice; it describes how the ruling changes the position of each.
For claimants' counsel. The general causation risk that justified a wait-and-see posture on unfiled claims has receded. The more pressing work is client-level: documenting duration and frequency of use, Product Identification across brands, diagnosis records, and competing risk factors, because those are the variables that will decide case-specific Rule 702 motions and any settlement grid. Firms should also watch PFS compliance closely; the court's October dismissals show it will clear deficient cases from the docket. Counsel with ovarian cancer clients have particular reason to obtain Dkt. 2092 and determine whether either excluded expert addressed ovarian cancer.
For defendants. The opportunity for a docket-wide win on general causation has largely passed, leaving three levers: the ruling on the last two experts, case-specific challenges in the January motions, and the bellwether trials themselves. Each defendant can still argue its formulations and warnings differed from its competitors', but because the court accepted relaxers as a product category for general causation, those arguments move to Product Identification and Specific Causation. With state attorney general actions in Arizona and Minnesota that do not depend on proving causation, L'Oréal carries the most concentrated exposure.
For funders and portfolio investors. Third-Party Litigation Funding in mass torts prices the binary general causation risk heavily, and in this docket that risk has now been substantially resolved in the plaintiffs' favor. The remaining risks are timing (a first trial in September 2027, with any settlement likely to follow trial results rather than precede them), case quality across inventories that grew quickly, and allocation between uterine and ovarian claims. Portfolios with weak documentation or high PFS deficiency rates face the court's dismissals regardless of the expert rulings.
For claimants themselves. A person considering a claim should understand that the ruling means the federal court will let juries hear scientific evidence that hair relaxers can cause uterine and ovarian cancer. It does not mean any individual claim will succeed, that a settlement is coming, or when money would be paid. No hair relaxer settlement exists, and anyone told otherwise should ask for the court document that says so.
FAQ
What did the judge decide about the hair relaxer experts on November 12?
Judge Mary M. Rowland denied the defendants' motion to exclude four of the plaintiffs' general causation experts and granted it as to two, in an order a plaintiff-side docket summary identifies as Dkt. 2092 in MDL No. 3060. It was the second installment of her ruling on the defendants' May 5, 2026 Rule 702 motion.
Which hair relaxer experts were excluded?
The two experts excluded on November 12, 2026 have not been publicly identified. They are among the eight general causation experts the court had not addressed on October 22: Brown, Chang, Crowley, Panigrahy, Puglisese, Roque, Sharma and Zoeller, as listed in the May 2026 joint status report. The order itself names them and is available on the MDL docket.
How many hair relaxer experts can testify at trial?
Six of the ten challenged general causation experts can testify in some form: five in full, including epidemiologist Dr. Cote, and toxicologist Mr. Atwood in part. Two are excluded and two await a ruling.
Is the hair relaxer lawsuit still going?
Yes. MDL 3060 had 12,743 pending actions as of the JPML's November 2, 2026 report, the plaintiffs' central causation evidence has been admitted, and the first bellwether trial is set for September 2027.
Has there been a hair relaxer settlement?
No. As of November 14, 2026, there is no hair relaxer settlement in the federal MDL, and no trial has taken place. The expert rulings increase the defendants' exposure but do not themselves create a settlement.
When is the first hair relaxer trial?
The first federal bellwether trial is scheduled for September 7, 2027, according to a September 2026 docket entry, with one report giving September 9, 2027. Summary judgment and case-specific Rule 702 motions in the bellwether cases are reported as due January 11, 2027.
Published for legal professionals. Analysis and summaries only — not legal advice, and no attorney-client relationship is created by use of this site.
Read next

Hair Relaxer Daubert Ruling: Judge Admits Key Cancer Expert as Final Five MDL 3060 Bellwethers Are Set
In an October 22 hair relaxer Daubert ruling, Judge Mary Rowland refused to exclude the plaintiffs' epidemiologist in the hair relaxer MDL and limited a second causation expert only in part. The same day she fixed the five bellwether cases. With 12,381 cases pending, the federal litigation is still alive.
Torts Desk · 23 min

Hair Relaxer Bellwether Trial Date Set: First MDL 3060 Trial Starts September 7, 2027
A 24 September 2026 docket entry fixed the hair relaxer bellwether trial date at 7 September 2027 and set eight monthly conferences before it. The case has not been picked, the Rule 702 general causation motion is still undecided, and 12,129 federal claims wait on the result.
Torts Desk · 23 min

Baby Food Autism Lawsuit Ruling: Judge Ends Autism and ADHD Claims in MDL 3101, IQ Claims Survive
On October 14, Judge Jacqueline Scott Corley granted partial summary judgment to Gerber, Walmart, Beech-Nut and other makers, holding that plaintiffs have no admissible general causation evidence for autism or ADHD. IQ-loss, learning-disability and formula claims live on, and Texas has just sued Gerber.
Torts Desk · 18 min